{"id":"benazepril-valsartan","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperkalemia"},{"rate":null,"effect":"Cough"},{"rate":null,"effect":"Hypotension"}]},"_chembl":{"chemblId":"CHEMBL1069","moleculeType":"Small molecule","molecularWeight":"435.53"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benazepril inhibits angiotensin-converting enzyme (ACE), preventing the conversion of angiotensin I to angiotensin II, while valsartan blocks the angiotensin II type 1 (AT1) receptor directly. Together, these agents provide dual blockade of the renin-angiotensin-aldosterone system, resulting in greater vasodilation, reduced aldosterone secretion, and more effective blood pressure reduction than either agent alone.","oneSentence":"Benazepril/Valsartan is a combination of an ACE inhibitor and an angiotensin II receptor blocker that reduces blood pressure by inhibiting two complementary pathways of the renin-angiotensin-aldosterone system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:54.574Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT07262710","phase":"","title":"Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers With Post-Stroke Pneumonia: A Real-World Retrospective Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"First Teaching Hospital of Tianjin University of Traditional Chinese Medicine","startDate":"2025-12-01","conditions":"Post-stroke Pneumonia","enrollment":13656},{"nctId":"NCT05498675","phase":"","title":"Effect of Sacubitril/Valsartan on Cardiac Function in Hypertensive Patients Stratified by BMI: A Real World Study","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2021-09-01","conditions":"Sacubitril/Valsartan, Hypertension, Obesity","enrollment":180},{"nctId":"NCT00309257","phase":"PHASE2","title":"Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2004-01","conditions":"Alport Syndrome","enrollment":9},{"nctId":"NCT04467931","phase":"","title":"ACEI or ARB and COVID-19 Severity and Mortality in US Veterans","status":"COMPLETED","sponsor":"University of Utah","startDate":"2020-01-19","conditions":"Hypertension, COVID","enrollment":22213},{"nctId":"NCT04330300","phase":"PHASE4","title":"Coronavirus (COVID-19) ACEi/ARB Investigation","status":"SUSPENDED","sponsor":"National University of Ireland, Galway, Ireland","startDate":"2020-04-30","conditions":"Hypertension, COVID-19","enrollment":2414},{"nctId":"NCT00503152","phase":"PHASE3","title":"Preventing Microalbuminuria in Type 2 Diabetes","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2007-05","conditions":"Diabetes","enrollment":612},{"nctId":"NCT01715584","phase":"PHASE4","title":"Is There an Adverse Drug Reaction Between Renin-Angiotensin System Blockade and Inhaled Anesthetics","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2012-07","conditions":"Hypertension","enrollment":80},{"nctId":"NCT00000620","phase":"PHASE3","title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD)","status":"COMPLETED","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"1999-09","conditions":"Atherosclerosis, Cardiovascular Diseases, Hypercholesterolemia","enrollment":10251},{"nctId":"NCT00494715","phase":"PHASE3","title":"Preventing ESRD in Overt Nephropathy of Type 2 Diabetes","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2007-05","conditions":"Diabetes","enrollment":102},{"nctId":"NCT00721773","phase":"NA","title":"Renal Protective Effects of Renin Angiotensin System (RAS) Inhibitor in Peritoneal Dialysis Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2008-09","conditions":"Renal Function Disorder","enrollment":200},{"nctId":"NCT01917149","phase":"PHASE4","title":"Supramaximal Titrated Inhibition of RAAS in Dilated Cardiomyopathy","status":"COMPLETED","sponsor":"Xijing Hospital","startDate":"2005-03","conditions":"Dilated Cardiomyopathy","enrollment":480},{"nctId":"NCT01375322","phase":"PHASE4","title":"ADDM Study - Amtrel and Co-Diovan in Type 2 Diabetes Mellitus Hypertension Patients With Microalbuminuria","status":"COMPLETED","sponsor":"TSH Biopharm Corporation Limited","startDate":"2007-06","conditions":"Hypertension, Diabetes Mellitus, Type 2, Albuminuria","enrollment":226},{"nctId":"NCT00664846","phase":"NA","title":"Standard Medical Management in Secondary Prevention of Ischemic Stroke in China","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2008-04","conditions":"Stroke","enrollment":4000},{"nctId":"NCT00691314","phase":"NA","title":"Efficacy and Safety of Stent Implantation in Symptomatic Extra- and Intracranial Artery Stenosis","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2008-06","conditions":"Stroke, Transient Ischemic Attack, Atherosclerosis","enrollment":300},{"nctId":"NCT00171119","phase":"PHASE4","title":"A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-01","conditions":"Hypertension, Diabetic Nephropathy","enrollment":81},{"nctId":"NCT00684489","phase":"NA","title":"Renin-Guided Therapeutics in the Management of Untreated, Uncontrolled, or Complicated Hypertension","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2003-09","conditions":"Hypertension","enrollment":52}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Benazepril/Valsartan","genericName":"Benazepril/Valsartan","companyName":"Mario Negri Institute for Pharmacological Research","companyId":"mario-negri-institute-for-pharmacological-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benazepril/Valsartan is a combination of an ACE inhibitor and an angiotensin II receptor blocker that reduces blood pressure by inhibiting two complementary pathways of the renin-angiotensin-aldosterone system. Used for Hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}